vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Eastern Bankshares, Inc. (EBC). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $196.0M, roughly 1.5× Axsome Therapeutics, Inc.). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs -14.6%, a 36.6% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs 65.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 38.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
AXSM vs EBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $295.9M |
| Net Profit | $-28.6M | $65.3M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 22.1% |
| Revenue YoY | 65.0% | 710.6% |
| Net Profit YoY | 61.9% | -34.4% |
| EPS (diluted) | $-0.55 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $295.9M | ||
| Q4 25 | $196.0M | $37.5M | ||
| Q3 25 | $171.0M | $241.5M | ||
| Q2 25 | $150.0M | $244.9M | ||
| Q1 25 | $121.5M | $31.1M | ||
| Q4 24 | $118.8M | $216.5M | ||
| Q3 24 | $104.8M | $203.4M | ||
| Q2 24 | $87.2M | $154.0M |
| Q1 26 | — | $65.3M | ||
| Q4 25 | $-28.6M | $99.5M | ||
| Q3 25 | $-47.2M | $106.1M | ||
| Q2 25 | $-48.0M | $100.2M | ||
| Q1 25 | $-59.4M | $-217.7M | ||
| Q4 24 | $-74.9M | $60.8M | ||
| Q3 24 | $-64.6M | $-6.2M | ||
| Q2 24 | $-79.3M | $26.3M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | 38.9% | ||
| Q2 25 | -24.5% | 41.0% | ||
| Q1 25 | -46.9% | -590.9% | ||
| Q4 24 | -61.1% | 33.3% | ||
| Q3 24 | -59.8% | -1.6% | ||
| Q2 24 | -89.5% | 24.7% |
| Q1 26 | — | 22.1% | ||
| Q4 25 | -14.6% | 265.6% | ||
| Q3 25 | -27.6% | 44.0% | ||
| Q2 25 | -32.0% | 40.9% | ||
| Q1 25 | -48.9% | -699.2% | ||
| Q4 24 | -63.1% | 28.1% | ||
| Q3 24 | -61.7% | -3.0% | ||
| Q2 24 | -91.0% | 17.1% |
| Q1 26 | — | $0.29 | ||
| Q4 25 | $-0.55 | $0.48 | ||
| Q3 25 | $-0.94 | $0.53 | ||
| Q2 25 | $-0.97 | $0.50 | ||
| Q1 25 | $-1.22 | $-1.08 | ||
| Q4 24 | $-1.54 | $0.29 | ||
| Q3 24 | $-1.34 | $-0.03 | ||
| Q2 24 | $-1.67 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $551.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $4.3B |
| Total Assets | $689.8M | $30.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $551.7M | ||
| Q4 25 | $322.9M | $507.6M | ||
| Q3 25 | $325.3M | $703.4M | ||
| Q2 25 | $303.0M | $948.3M | ||
| Q1 25 | $300.9M | $609.0M | ||
| Q4 24 | $315.4M | $1.9B | ||
| Q3 24 | $327.3M | $1.7B | ||
| Q2 24 | $315.7M | $1.4B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $88.3M | $4.3B | ||
| Q3 25 | $73.7M | $3.8B | ||
| Q2 25 | $73.1M | $3.7B | ||
| Q1 25 | $53.2M | $3.6B | ||
| Q4 24 | $57.0M | $3.6B | ||
| Q3 24 | $92.9M | $3.7B | ||
| Q2 24 | $102.9M | $3.0B |
| Q1 26 | — | $30.6B | ||
| Q4 25 | $689.8M | $30.6B | ||
| Q3 25 | $669.3M | $25.5B | ||
| Q2 25 | $639.8M | $25.5B | ||
| Q1 25 | $596.7M | $25.0B | ||
| Q4 24 | $568.5M | $25.6B | ||
| Q3 24 | $561.5M | $25.5B | ||
| Q2 24 | $548.2M | $21.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $432.4M | ||
| Q3 25 | $1.0M | $157.1M | ||
| Q2 25 | $-32.4M | $123.9M | ||
| Q1 25 | $-43.4M | $47.3M | ||
| Q4 24 | $-26.2M | $283.8M | ||
| Q3 24 | $-18.6M | $108.3M | ||
| Q2 24 | $-30.1M | $54.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.35× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.67× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
